Sagimet Biosciences INC. (SGMT) — SEC Filings

Overview

Sagimet Biosciences INC. (SGMT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 21, 2026: Sagimet Biosciences Inc. filed an 8-K on April 21, 2026, reporting on the departure of certain officers and compensatory arrangements. The filing also includes other events, with the period of report being April 20, 2026. Specific details regarding the departures and compensatory arrangements are no

Sentiment Summary

Across 48 filings, the sentiment breakdown is: 2 bullish, 3 bearish, 43 neutral. The dominant filing sentiment for Sagimet Biosciences INC. is neutral.

Filing Type Overview

Sagimet Biosciences INC. (SGMT) has filed 28 8-K, 6 10-Q, 2 10-K, 5 SC 13G, 3 SC 13G/A, 1 8-K/A, 1 DEF 14A, 1 S-1/A, 1 S-1 with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (48)

• Sagimet Biosciences Files 8-K on Officer Changes — 8-K · Apr 21, 2026 Risk: medium
  Sagimet Biosciences Inc. filed an 8-K on April 21, 2026, reporting on the departure of certain officers and compensatory arrangements. The filing also includes
• Sagimet Biosciences Files 8-K Report — 8-K · Dec 18, 2025 Risk: low
  On December 18, 2025, Sagimet Biosciences Inc. filed an 8-K report. The filing indicates a Regulation FD Disclosure, Other Events, and Financial Statements and
• 8-K Filing — 8-K · Dec 17, 2025
• Sagimet's Cash Dwindles Amid Rising R&D, MASH & Acne Trials Advance — 10-Q · Nov 13, 2025 Risk: high
  Sagimet Biosciences Inc. reported a net loss of $12.908 million for the three months ended September 30, 2025, an improvement from a net loss of $14.619 million
• Sagimet Biosciences Files 8-K — 8-K · Oct 23, 2025 Risk: low
  Sagimet Biosciences Inc. filed an 8-K on October 23, 2025, reporting on financial statements and exhibits. The company, formerly known as 3-V Biosciences, Inc.,
• Sagimet Biosciences Changes Independent Auditor — 8-K · Aug 22, 2025 Risk: low
  Sagimet Biosciences Inc. announced on August 18, 2025, a change in its certifying accountant. The company has appointed PricewaterhouseCoopers LLP as its new in
• Sagimet Biosciences Terminates Material Agreement — 8-K · Aug 14, 2025 Risk: medium
  On August 14, 2025, Sagimet Biosciences Inc. filed an 8-K report detailing the termination of a material definitive agreement. The filing also includes informat
• Sagimet Biosciences Files 8-K on Financials — 8-K · Aug 13, 2025 Risk: low
  Sagimet Biosciences Inc. filed an 8-K on August 13, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD
• Sagimet's Losses Double Amid R&D Surge, Cash Dwindles — 10-Q · Aug 13, 2025 Risk: high
  Sagimet Biosciences Inc. reported a significant increase in net loss for the six months ended June 30, 2025, reaching $28.56 million, up from $14.75 million in
• Sagimet Biosciences Reports Board Changes and Officer Appointments — 8-K · Jun 10, 2025 Risk: medium
  On June 6, 2025, Sagimet Biosciences Inc. filed an 8-K report detailing changes in its board of directors and the election of new officers. The filing also addr
• Sagimet Biosciences Files 8-K — 8-K · Jun 4, 2025 Risk: low
  On June 4, 2025, Sagimet Biosciences Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No
• Sagimet Biosciences Files 8-K Report — 8-K · May 8, 2025 Risk: low
  On May 8, 2025, Sagimet Biosciences Inc. filed an 8-K report detailing results of operations, other events, and financial statements. The company, formerly know
• Sagimet Biosciences Files Q1 2025 10-Q — 10-Q · May 8, 2025 Risk: low
  Sagimet Biosciences Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as 3-V Biosciences, Inc., reported financial data incl
• Sagimet Biosciences Announces Board and Executive Changes — 8-K · Apr 30, 2025 Risk: medium
  Sagimet Biosciences Inc. announced on April 29, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company elect
• Sagimet Biosciences Files 8-K Report — 8-K · Mar 12, 2025 Risk: low
  On March 12, 2025, Sagimet Biosciences Inc. filed an 8-K report detailing results of operations and financial condition, along with other events and financial s
• Sagimet Biosciences Files 2024 10-K — 10-K · Mar 12, 2025 Risk: medium
  Sagimet Biosciences Inc. filed its 2024 10-K on March 12, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, f
• Sagimet Biosciences Files 8-K — 8-K · Mar 11, 2025 Risk: low
  Sagimet Biosciences Inc. filed an 8-K on March 11, 2025, reporting other events and financial statements. The company, formerly known as 3-V Biosciences, Inc.,
• Sagimet Biosciences Inc. Files Current Report — 8-K · Feb 14, 2025 Risk: low
  Sagimet Biosciences Inc. reported on February 14, 2025, that its Series A Common Stock trades under the symbol SGMT on The Nasdaq Global Market. The company, in
• Sagimet Biosciences Files 8-K Report — 8-K · Jan 2, 2025 Risk: low
  On January 2, 2025, Sagimet Biosciences Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific
• SC 13G Filing — SC 13G · Nov 14, 2024
• Sagimet Biosciences Inc. Files 8-K on Financials — 8-K · Nov 14, 2024 Risk: low
  Sagimet Biosciences Inc. filed an 8-K on November 14, 2024, reporting on its results of operations and financial condition. The filing includes financial statem
• Sagimet Biosciences Q3 2024 Update: Financial Snapshot — 10-Q · Nov 14, 2024 Risk: medium
  Sagimet Biosciences Inc. filed its 10-Q for the period ending September 30, 2024. The company reported cash and cash equivalents of $30.7 million. Key financia
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Sagimet Biosciences Enters Material Definitive Agreement — 8-K · Aug 16, 2024 Risk: medium
  On August 15, 2024, Sagimet Biosciences Inc. entered into a Material Definitive Agreement. The filing also includes financial statements and exhibits related to
• Gilead Acquires Sagimet Biosciences for $275M — 8-K · Aug 14, 2024 Risk: medium
  Sagimet Biosciences Inc. announced on August 14, 2024, that it has entered into a definitive agreement to be acquired by Gilead Sciences, Inc. for $275 million
• Sagimet Biosciences Q2 2024: Net Loss of $21.4M — 10-Q · Aug 14, 2024 Risk: medium
  Sagimet Biosciences Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $30.4 million and total liabilities of $1.5 mi
• Sagimet Biosciences Appoints New Directors, Adjusts Executive Pay — 8-K · Aug 1, 2024 Risk: medium
  Sagimet Biosciences Inc. announced on July 30, 2024, changes in its board of directors and executive compensation arrangements. Specifically, the company electe
• Sagimet Biosciences Files 8-K Report — 8-K · Jul 2, 2024 Risk: low
  On July 2, 2024, Sagimet Biosciences Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no other specific events de
• Sagimet Biosciences Files 8-K/A Amendment — 8-K/A · Jun 13, 2024 Risk: low
  Sagimet Biosciences Inc. filed an amendment (8-K/A) on June 13, 2024, to its previous report dated June 5, 2024. This amendment primarily concerns the filing of
• Sagimet Biosciences Holds 2024 Annual Meeting, Elects Directors — 8-K · Jun 6, 2024 Risk: low
  On June 5, 2024, Sagimet Biosciences Inc. filed an 8-K report detailing the results of its 2024 Annual Meeting of Stockholders held on June 4, 2024. The company
• Sagimet Biosciences Files 8-K Report — 8-K · May 23, 2024 Risk: low
  On May 23, 2024, Sagimet Biosciences Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. The
• Sagimet Biosciences Files 8-K on Operations and Financials — 8-K · May 15, 2024 Risk: low
  Sagimet Biosciences Inc. filed an 8-K on May 15, 2024, to report on its results of operations and financial condition, as well as to file financial statements a
• Sagimet Biosciences Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 15, 2024 Risk: low
  Sagimet Biosciences Inc. (SGMT) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Sagimet Biosciences Inc. filed a 10-Q for the period ending March
• Sagimet Biosciences Appoints New Directors, Adjusts Executive Pay — 8-K · May 6, 2024 Risk: low
  Sagimet Biosciences Inc. announced on May 3, 2024, changes in its board of directors and executive compensation. Specifically, the company elected two new direc
• Sagimet Biosciences Inc. Announces 2024 Annual Meeting of Stockholders on June 5, 2024 — DEF 14A · Apr 18, 2024 Risk: low
  Sagimet Biosciences Inc. (SGMT) filed a Proxy Statement (DEF 14A) with the SEC on April 18, 2024. Sagimet Biosciences Inc. will hold its 2024 Annual Meeting of
• Sagimet Biosciences Appoints New CMO and CSO — 8-K · Mar 25, 2024 Risk: medium
  On March 20, 2024, Sagimet Biosciences Inc. announced the appointment of Dr. Michael R. McDevitt as Chief Medical Officer and Dr. Jeffrey W. Allen as Chief Scie
• Sagimet Biosciences Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 25, 2024 Risk: medium
  Sagimet Biosciences Inc. (SGMT) filed a Annual Report (10-K) with the SEC on March 25, 2024. Sagimet Biosciences Inc. filed its annual report on Form 10-K for t
• SC 13G/A Filing — SC 13G/A · Mar 11, 2024
• SC 13G Filing — SC 13G · Feb 14, 2024
• SC 13G Filing — SC 13G · Feb 14, 2024
• SC 13G Filing — SC 13G · Feb 14, 2024
• FMR LLC & Abigail Johnson Trim Sagimet Stake to 8.991% — SC 13G/A · Feb 9, 2024 Risk: low
  FMR LLC, a major investment firm, and its principal owner, Abigail P. Johnson, have updated their ownership stake in Sagimet Biosciences Inc. (NASDAQ: SGMT). As
• Point72 Asset Management Takes 5.0% Stake in Sagimet Biosciences — SC 13G · Feb 5, 2024
  Point72 Asset Management, L.P., a hedge fund based in Stamford, CT, has disclosed a significant stake in Sagimet Biosciences Inc. (NASDAQ: SGMT). As of February
• Sagimet Biosciences 8-K: Executive Compensation Arrangements Updated — 8-K · Feb 2, 2024
  Sagimet Biosciences Inc. filed an 8-K on February 2, 2024, reporting an event that occurred on January 31, 2024, related to changes in its executive compensatio
• Sagimet Biosciences Files 8-K, Confirms Nasdaq Listing — 8-K · Jan 30, 2024
  Sagimet Biosciences Inc. filed an 8-K on January 30, 2024, reporting an event that occurred on January 25, 2024. This filing primarily serves to update administ
• Sagimet Biosciences Inc. Files Amendment to S-1 Registration Statement — S-1/A · Jan 24, 2024 Risk: low
  Sagimet Biosciences Inc. (SGMT) filed a Amended IPO Registration (S-1/A) with the SEC on January 24, 2024. Sagimet Biosciences Inc. filed an amendment (S-1/A) t
• Sagimet Biosciences Inc. Files S-1 for Potential IPO — S-1 · Jan 23, 2024 Risk: medium
  Sagimet Biosciences Inc. (SGMT) filed a IPO Registration (S-1) with the SEC on January 23, 2024. Sagimet Biosciences Inc. has filed an S-1 registration statemen
• Sagimet Biosciences Files 8-K for Compliance, Nasdaq Listing Confirmed — 8-K · Jan 22, 2024
  Sagimet Biosciences Inc. filed an 8-K on January 22, 2024, primarily to satisfy filing obligations related to written communications under Rule 425 of the Secur

Related Companies

MDGL · VKTX · GILD

Frequently Asked Questions